BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23553850)

  • 1. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
    Sharma MR; Karrison TG; Kell B; Wu K; Turcich M; Geary D; Kang SP; Takebe N; Graham RA; Maitland ML; Schilsky RL; Ratain MJ; Cohen EE
    Clin Cancer Res; 2013 Jun; 19(11):3059-67. PubMed ID: 23553850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
    Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
    Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
    Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
    LoRusso PM; Piha-Paul SA; Mita M; Colevas AD; Malhi V; Colburn D; Yin M; Low JA; Graham RA
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):193-202. PubMed ID: 23064958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
    Graham RA; Hop CE; Borin MT; Lum BL; Colburn D; Chang I; Shin YG; Malhi V; Low JA; Dresser MJ
    Br J Clin Pharmacol; 2012 Nov; 74(5):788-96. PubMed ID: 22458643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
    Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
    Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
    Chanu P; Musib L; Wang X; Cheeti S; Girish S; Bruno R; Lu T; Reddy J; Jin JY; Caro I
    J Invest Dermatol; 2021 Apr; 141(4):930-933. PubMed ID: 32976880
    [No Abstract]   [Full Text] [Related]  

  • 10. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
    Graham RA; Chang I; Jin JY; Wang B; Dufek MB; Ayache JA; Ezzet F; Zerivitz K; Low JA; Dresser MJ
    J Cardiovasc Pharmacol; 2013 Jan; 61(1):83-9. PubMed ID: 23107871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
    Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
    Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.
    Dreno B; Basset-Seguin N; Caro I; Yue H; Schadendorf D
    Oncologist; 2014 Aug; 19(8):790-6. PubMed ID: 25001266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
    LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
    Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
    Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
    Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
    Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
    Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.